Global Preeclampsia Diagnostics Market 2026 – 2035

To drive the growth of the market, the global Preeclampsia Diagnostics market is projected to grow to about USD 1.15 billion as early as 2025, and is expected to grow to an even higher level of close to USD 1.19 billion by 2026, and to continue its growth to approximately USD 1.59 billion by 2035 with a CAGR of 3.3% over the next 10 year forecast of 2026-2035 on account of the rising prevalence of pregnancy-related hypertensive disorders and increased awareness on maternal and fetal health.

Market Highlight

• The Diagnostics Preeclampsia market globally saw the greatest market in North America which will contribute approximately 38% of the total market with supporting factors of better maternal healthcare facilities, the increase in birth rates, and the enhancement of government emphasis on prenatal screening programs.

• APAC is expected to register a consistent growth of 3.6% during the period between 2026 and 2035 due to high levels of adoption of advanced diagnostic tools, understanding with regard to the complications that occur during pregnancy, and the existence of well-developed healthcare systems.

• By type of test, tests based on biomarkers were the largest at almost 60% in 2025 with the increasing applications in the prevention of preeclampsia risk at an early and accurate stage.

• The analysis of the urine kits will be the highest growing item at a CAGR of 3.5% in the forecast period; this is because the urine kits are cost effective, easy to handle, and can be used in routine screening.

• Market In terms of use, early screening is expected to take over the market with about 40% of the market in 2025 compared to risk assessment with the highest CAGR of 3.4% between 2026 and 2035 as more interest shifts to preventive care for the mother.

• By end-user, hospitals will represent the highest proportion of more than 58% in 2025, owing to the presence of holistic diagnostic services and increased patient traffic in prenatal care.

• The adoption is also on the increase in maternity clinics and home care settings which is facilitated by the growing need for point-of-care diagnostics and continuous monitoring in high risk pregnancies.

Significant Growth Factors

• Enhancing the application of early Detection tests that use biomarkers: The increased interest regarding the development of a method to identify the risk of preeclampsia at an earlier stage, using the means of biomarkers, such as sFlt-1 and PlGF, makes the advanced diagnostic systems even more popular. The tests assist the clinicians to diagnose the situation before the critical complications arise therefore improving maternal and fetal outcomes. In February 2024, Roche Diagnostics announced that it had invented its Elecsys sFlt-1/PlGF ratio assay, which enhanced the clinical decision-making process concerning the early detection and management of preeclampsia in high-risk pregnancies.

• Desire to learn more about Prenatal monitoring and Maternity Health Interventions: The governments and healthcare organizations in the world are ramping up the antenatal programs and routine check-ups on pregnancy complications, including preeclampsia. This is largely experienced in the developing world whereby the savings of maternal deaths are a priority. In order to improve early diagnosis and management of hypertensive pregnancy conditions, the World Health Organization reinforced the recommendations on newborn-reinforced antenatal care to include regular blood pressure and urine protein screening in pregnancy.

• Non-Invasive and Point-of-Care Technologies: Technological Advancements: There is a shifting trend towards less invasive and faster types of the diagnostic procedure which may be performed in a timely fashion not under the natural laboratory conditions. The point-of-care solutions are increasing access especially within the rural and resources-handicapped areas. In October 2024, Siemens Healthineers declared that it had enhanced its point-of-care diagnostic line, which aids in performing maternal health testing quicker and more accurately and parameters that might be applied in identifying preeclampsia.

• Enhancing the Digital Health and Remote Health Solutions Adoption: The introduction of digital health devices and wearable technologies is enabling tracking of blood pressure and maternal levels of health in the long term, which makes it possible to intervene in case of high-risk pregnancy. In January 2025, GE HealthCare integrated digital capabilities into the maternal monitoring solutions to improve remote monitoring of complications of pregnancy like hypertensive diseases like preeclampsia.

What are the Major Advances Changing the Preeclampsia Diagnostics Market Today?

• Movement to Higher Biomarker-Based Risk Prognostication: The situation with diagnostics is changing very fast due to the introduction of biomarker-based diagnostics like the sFlt-1/PlGF ratio that allow identifying the risk of preeclampsia much earlier and being able to predict the risk of developing it much earlier before clinical symptoms become dire. These tests have been enhancing the clinical decision-making as they assist the physicians to stratify the patient and manage the high-risk pregnancies. In March 2024, Roche Diagnostics improved its Elecsys immunoassay system to provide a faster and more accurate analysis of biomarkers to be used in clinical environments in measuring the risk of pre-eclampsia.

• Development of Rapid Testing Solutions and Point-of-Care: Recent trends in this area are the shift to point-of-care (POC) diagnostics where local and remote detection of preeclampsia can happen faster. These solutions eliminate the reliance on centralized labs and aid real-time clinical decision-making, particularly where there are limited resources. In September 2024, Abbott Laboratories added to its rapid diagnostics line with upgraded handhelds that can be used to test maternal health, such as parameters related to pregnancy disorders that are associated with hypertension.

• Digital Monitoring and Connected Maternal Health Platforms: This feature is integrated into the PHR, allowing it to retrieve all stays and broadcast the patient's health monitoring data to the mobile application. Digital Monitoring and Connected Maternal Health Platforms: This functionality is implemented in the PHR, which enables it to access all stays and transmit patient health monitoring data to the mobile application. Digital health technologies are actively involved in constant control of blood pressure and other vital parameters related to preeclampsia. The links between platforms allow tracking of data in real-time and provide early warnings, which enhances the current performance in the form of timely intervention. GE HealthCare also launched new remote monitoring solutions in combination with maternal care systems in January 2025 to assist in detecting and managing complications related to pregnancies at an early stage.

• Improvement in Non-Invasive and Multi-parameter Diagnostic Models: Non-invasive testing innovations are also improving diagnostic accuracy and lowering the risk for the patient such as combined screening tests that are an integration of blood biomarkers, imaging, and clinical data. These methods are especially useful in case of screening at an early stage and follow-up. PerkinElmer enhanced its prenatal screening offerings in June 2023 with enhanced multi-marker testing solutions to enhance the ability to detect diseases in the early stages of the illness like preeclampsia.

Category Wise Insights

By Test Type

Why Tests that are based on Biomarkers are taking the market?

The pretentious nature of biomarker-based diagnostics in the preeclampsia diagnostics market is the highest given the fact that the conditions can be predicted accurately early enough before the severe symptoms occur. Biomarker tests that include sFlt-1 and PlGF can be used to determine the level of risk and make timely medical choices that enhance fetal and maternal outcomes. Such tests are now becoming a standard prenatal screening procedure in most advanced healthcare systems. Roche Diagnostics in March enhanced its Elecsys platform on how to improve biomarker-based risk assessment of preeclampsia in clinical settings.

Increasing Significance of Blood Pressure Measuring.

One of the most commonly used diagnostic methods to be used in the detection of preeclampsia is blood pressure monitoring since hypertension is one of the major clinical signs of preeclampsia. The continual availability of digital and wearable blood pressure equipment has enhanced continuous monitoring particularly when it comes to high risk pregnancies. They are finding their way into these clinical as well as home care facilities to be used as solutions so as to guarantee early prevention and prompt treatment. GE HealthCare launched more innovative maternal monitoring systems with digital tracking in January 2025 that would improve the management of hypertensive disorders in pregnancy.

What is the reason why Urine Analysis Kits are Growing at a Rapid Pace?

The urine analysis kits are undergoing tremendous growth because they are cheaper and easy to use in determining the presence of proteinuria which is a major symptom of preeclampsia. The kits are utilized mainly during the normal antenatal checkups and are especially useful in the low-resource environment where enhanced diagnostic facilities can be scarce. They are a crucial part of the primary screening due to their simplicity and fast outcomes. Siemens Healthineers has also introduced greater capacity of routine maternal health screening in its urinalysis portfolio as of July 2023.

• Increased adoption of Imaging techniques: Non-invasive imaging methods, like ultrasound, are emerging as significant in the determination of fetal growth and placental health in the suspected cases of preeclampsia. These techniques offer important data on fetal health and can be used in making clinical decisions on high-risk pregnancies. Technology in the imaging systems is enhancing the accuracy of diagnosing and the speed of work. Philips healthcare released enhanced ultrasound solutions in October 2024, which would enhance the maternal and fetal health assessment.

By Application

Why the Market is dominated by Early Screening?

The strongest area of application is the early screening because it is the most important in the detection of preeclampsia risk at an early age so that precautions can be taken to avoid risks and minimal complications. This segment is being driven by the rising awareness and introduction of routine prenatal screening programs. Later on, in June 2023, PerkinElmer added to its prenatal screening solutions to give better screening opportunities on pregnancy related issues such as preeclampsia.

• Paying More Attention to Risk Assessment: Risk assessment is becoming important of great magnitude since providers are trying to group patients into tiers according to their risk of acquiring preeclampsia. Such assessments are getting better due to the use of advanced diagnostic tools and algorithms. Thermo Fisher Scientific released new clinical research solutions in August of 2024 that aid the use of biomarkers as a measure of risk in maternal health.

By End-User

Why are Hospitals the Market Leaders?

The hospitals have the highest concentration in the preeclampsia diagnostics market because of the presence of advanced diagnostic infrastructures, professional staff, and increased flow of patients to the hospital seeking prenatal care. They are also prepared to deal with complicated and risky pregnancy cases that demand extensive diagnostic assistance. In May 2024, Hologic, Inc. enhanced the women-related health diagnostic portfolio to facilitate the hospital-based solutions of maternal care.

• Increasing Uptake in Maternity Clinics: Pregnant women are more and more treated in maternity clinics with specific diagnostic equipment used to conduct regular prenatal monitoring and to detect complications early (preeclampsia). These clinics are centered on individual care and constant surveillance. In September 2023, Abbott Laboratories extended the services available in maternal care diagnostics to aid the provision of point-of-care testing in outpatient and clinic services.

• Increasing the Diagnostic Laboratory Role: Diagnostic laboratories are significant in the high-tech tests of biomarkers and in the course of massive screening initiatives. The demand in this segment is also being pushed by the outsourcing of specialized diagnostic services. Eurofins Scientific increased capacity to perform diagnostic tests in April 2024 to meet the increasing demand of special maternal health testing.

• New Demand in Home Care: The home care environment is the one that is increasing in adoption as the number of remote monitoring solutions increases and the necessity to constantly monitor the maternal health parameters. This trend is especially useful with high-risk pregnancies that need frequent monitoring. In January 2025, Omron Healthcare also launched high-tech home-based blood pressure monitoring equipment that will enhance the management of maternal health.

Report Scope

Regional Analysis

Why did the Market in 2025 fall into the hands of Asia Pacific?

Asia Pacific dominated the market because of the growing awareness of maternal health, more governmental programs for decreasing maternal mortality, and providing better availability of prenatal care services. Other countries also play a serious role including China and India since they have a huge pool of population and an increasing interest in early pregnancy screening. The growth of the healthcare infrastructure and the rise of institutional deliveries are also stimulating the adoption of diagnostics even more. Roche Diagnostics has also added to its maternal health diagnostics services in the Asia Pacific in May 2024, to aid the early detection of pregnancy related complications such as preeclampsia.

China Market Trends

China is also one of the most active participants in the regional development because the government supports maternal healthcare interventions and adopts more and more sophisticated prenatal diagnostic methods. There is a change in the country toward the biomarker-based screening programs and the hospital-based monitoring programs of high-risk pregnancies. The expansion in the market is also supported by increasing investments in digitalizing healthcare and capability in laboratories. In August 2023, BGI Genomics developed the ability to test pregnancies with improved diagnostic tools and solutions that would help in detecting pregnancy-related conditions at earlier stages.

What is the motivation of the gradual upsurge in North America?

The high awareness rates, well-developed healthcare facilities, and the increase in the use of the latest diagnostic technologies allow North America to keep increasing. The area has a properly developed prenatal care framework and the emergence of biomarker-based and digital monitoring technologies to manage high-risk pregnancies. Innovation is also a driver of growth, and it is supported by the regulators. In January 2025, Thermo Fisher scientific increased capabilities in maternal health research and diagnostics to aid in the development of advanced screening technologies.

How large is the U.S. Market?

The U.S. market of Preeclampsia Diagnostics would grow to USD 0.37 million in 2025 and is likely to expand at the CAGR of about 4.2%.

U.S. Market Trends

The powering forces in the U.S. market are the growing adoption of more sophisticated prenatal screening technologies, the growing number of high-risk pregnancies, and the high adoption rate of digital health monitoring devices. An early diagnosis and patient management are being enhanced through the integration of AI and remote monitoring solutions. GE HealthCare reinforced its maternal monitoring solutions in the U.S. in April 2024 by adding modern digital integration of improved care during pregnancy.

Why do the Europeans care about quality and early detection?

Europe is a developed market with good regulatory structures, universal health policies and emphasis on early diagnosis and preventive care. The growth of the market is also influenced by the rising use of biomarker-based diagnostics and some organized prenatal screening programs. Demand is also being driven by government efforts to help in curbing maternal death. PerkinElmer increased its prenatal screening solutions in Europe in February, 2024, to add value to early diagnosis of complications during pregnancy.

Germany Market Trends

Germany is one of the most developed markets in Europe as the country has well-developed healthcare facilities and pays a lot of attention to maternal and fetal health. More innovative diagnostic tools and online health services to track pregnancy are also being used in the country. Cooperation among the research institutes and health care professionals is enhancing innovation. In June 2023, Merck KGaA invested in developing its life science in Germany to facilitate the development of advanced diagnostic and healthcare solutions.

What is the reason why the Middle East and Africa are emerging?

The Middle East & Africa region is one of the growth markets because of the increased investment in the healthcare infrastructure and awareness of maternal health. Gulf countries are working on the improvement of prenatal care services whereas the African countries are slowly advancing access to solutions in terms of diagnostics. Growth is also supported by international relationships and medical programs. Abbott Laboratories increased its footprint in the Middle East and Africa in the diagnostics segment in September 2024, to enhance maternal health testing solution availability.

Top Players in the Market and Their Offerings

• Roche Diagnostics

• Abbott Laboratories

• Siemens Healthineers

• GE HealthCare

• Thermo Fisher Scientific

• PerkinElmer

• Danaher Corporation

• bioMérieux

• QuidelOrtho Corporation

• Becton Dickinson and Company

• Hologic Inc.

• F. Hoffmann-La Roche Ltd.

• Others

Key Developments

The market is experiencing tremendous change with the major players concentrating on improving the diagnostic quality, broadening prenatal testing lines, and adopting high tech methods of early-stage detection and monitoring of preeclampsia.

• Thermo Fisher scientific increased its maternal health and biomarkers research solutions in January 2025 in order to help advance screening and risk assessment of pregnancy-related complications, more solidifying itself in prenatal diagnostics.

• In June 2023, PerkinElmer expanded prenatal screening with better multi-marker testing solutions that would help to make early diagnoses of diseases like preeclampsia and achieve better clinical outcomes.

The following are strategic changes that allow the companies to increase their technological capacities, increase their presence in the global arena, and meet the increasing need to determine preeclampsia more precisely and earlier in the disease progression.

The Preeclampsia Diagnostics Market is segmented as follows:

By Test Type

• Biomarker-Based Tests

• Blood Pressure Monitoring

• Urine Analysis Kits

• Imaging Techniques

By Application

• Early Screening

• Risk Assessment

• Maternal Health Monitoring

• Fetal Health Evaluation

By End-User

• Hospitals

• Maternity Clinics

• Diagnostic Laboratories

• Home Care Settings

Regional Coverage:

North America

• U.S.

• Canada

• Mexico

• Rest of North America 

Europe

• Germany

• France

• U.K.

• Russia

• Italy

• Spain

• Netherlands

• Rest of Europe

Asia Pacific

• China

• Japan

• India

• New Zealand

• Australia

• South Korea

• Taiwan

• Rest of Asia Pacific 

The Middle East & Africa

• Saudi Arabia

• UAE

• Egypt

• Kuwait

• South Africa

• Rest of the Middle East & Africa

Latin America

• Brazil

• Argentina

• Rest of Latin America